MALASSA Project Launched: NovoArc Develops Lipid Nanoparticle Platform for a New Antibody Therapy Against Lassa Fever
At the kick-off meeting in Amsterdam, the partners of the MALASSA project met in person for the first time. NovoArc is part of the consortium and contributes its expertise in lipid nanoparticles.
Eurostars project NO-PNP launched: a new approach to neuropathic pain
Together with Akasi Pharma and IVRS AB, NovoArc is developing a long-acting, non-opioid treatment for neuropathic pain. NovoArc is contributing its liposomal TEL platform to the project.
Gold for NovoArc at the Born Global Champion Awards
The award honors companies that successfully enter international markets at an early stage, demonstrate strong export performance, and show the potential to create lasting global impact.
We use cookies on our website. They help us to improve this website and the user experience (tracking cookies). You can decide for yourself whether you want to allow them.